Hanna Gaggin
Cardiovascular Disease · Boston, MANPI 1760597728
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $269,527 of the $350,203 with a category attached, or 77.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.0%. 2025 is the largest year on record at $156,336, 5.5 times the $28,613 reported in 2019. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $1563.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$81K
- AstraZeneca$67K
- Novo Nordisk AS$63K
- Pfizer$31K
- Novo Nordisk$31K
- Alnylam Pharmaceuticals Inc.$19K
- plus $59K from 11 others
Across 51 payments — averaging $42,977 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akcea Therapeutics, Inc.$775K
- Pfizer$349K
- Astrazeneca UK Limited$322K
- Alnylam Pharmaceuticals Inc.$203K
- Ionis Pharmaceuticals, Inc.$175K
- Roche Diagnostics International Ltd$147K
- plus $222K from 4 others
What the payments were for
- Consulting fees$269,52777%
- Speaking & faculty fees$20,2006%
- Travel & lodging$56,04716%
- Food & beverage$4,2311%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 81 | $80,588 |
| AstraZeneca(2 entities) | 19 | $66,844 |
| Novo Nordisk AS | 16 | $63,058 |
| Pfizer | 20 | $31,008 |
| Novo Nordisk | 14 | $30,953 |
| Alnylam Pharmaceuticals Inc. | 17 | $18,884 |
| Abbott | 28 | $16,207 |
| Bridgebio Pharma, Inc. | 6 | $13,593 |
| Amgen | 3 | $9,900 |
| Roche Diagnostics International Ltd | 6 | $8,857 |
| Roche Diagnostics Corporation | 8 | $5,885 |
| Eko Health, Inc. | 1 | $4,000 |
| Radiometer America, Inc | 1 | $250 |
| Edwards Lifesciences | 1 | $91 |
| Akcea Therapeutics, Inc. | 1 | $50 |
| Pfizer Pharmaceuticals Korea Limited | 1 | $22 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$31,001
- Attruby$13,451
- Ozempic$10,523
- AMVUTTRA$9,945
- RDI Research$8,749
- CD cobas Reagents$5,776
- VERQUVO$5,373
- Tendyne Mitral Valve System$3,982
- WAINUA$3,250
- Absorb GT1$2,488
- AQT90$250
How this compares
$350,203 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 581 | $13,514,092 |
| VyndaqelTafamidis Meglumine | 63 | $1,338,537 |
| JardianceEmpagliflozin | 94 | $130,753 |
| EliquisApixaban | 48 | $79,636 |
| EntrestoSacubitril/Valsartan | 38 | $54,210 |
| FarxigaDapagliflozin Propanediol | 37 | $50,576 |
| Repatha SureclickEvolocumab | 24 | $34,317 |
| XareltoRivaroxaban | 20 | $30,641 |
| Eplerenone | 34 | $2,720 |
| Metoprolol Succinate | 107 | $2,513 |
| Atorvastatin Calcium | 101 | $1,590 |
| Torsemide | 38 | $1,484 |
| Ezetimibe | 26 | $1,296 |
| Rosuvastatin Calcium | 30 | $1,113 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $31,008 | $14,932,265692 claims |
| Boehringer IngelheimJardiance | $14 | $130,75394 claims |
| AstraZenecaFarxiga | $66,844 | $50,57637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.